/
RSS Feed
SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamer?s investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Merck?s anti-PD-1 therapy, KEYTRUDA? (pembrolizumab) in patients with selected advanced solid tumors. Collaboration with Merck Under
